GHRH
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A 44-amino-acid hormone that triggers pulsatile growth hormone release, marketed via analogs for body composition, recovery, and sleep. The mechanism is well proven, and one analog has solid human trial data for cutting visceral fat, while cognitive benefits have limited controlled human evidence from GHRH analogs and organ-protection claims remain preclinical. Chronic use raises IGF-1 and injection reactions, with an unresolved tumor-growth concern. One formulation is FDA-approved; other products are unregulated.
Read Full recordStudied uses & evidence
Studied uses(6)
Physiological stimulation of endogenous GH release in a pulsatile, regulated manner
MediumNative GHRH studies and tesamorelin's FDA label confirm pulsatile, not flat, GH release.
Improved body composition (reduced visceral fat) via tesamorelin in HIV lipodystrophy
HighConfirmed in phase 3 RCTs and a 2026 meta-analysis; benefit reverses on stopping.
Neuroprotective and anti-inflammatory effects in retinal degeneration models
LowRodent studies only; synthetic analogs protected retinal cells, no human trials exist.
Evidence limits
- Evidence Level
- Strong Evidence (analogs FDA-approved)
GHRH analogs have a robust clinical evidence base. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy based on Phase 3 trials showing significant reduction in visceral adipose tissue. Sermorelin was FDA-approved for pediatric GH deficiency (now discontinued in US). Clinical trials have also explored GHRH analogs for age-related GH decline, cognitive function in older adults, and sleep improvement. Native GHRH is used clinically as a diagnostic agent for GH deficiency. The overall evidence base for GHRH-system therapeutics is substantial with thousands of human participants across multiple indications.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNot recommended for children outside a clinical study or an approved pediatric indication; GHRH has been studied in children with GH deficiency.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site reactions (swelling, redness, pain)
HighElevated IGF-1 levels with chronic use
HighFluid retention, joint pain, carpal tunnel (GH-related effects)
ModeratePotential tumor growth stimulation in GH-sensitive cancers
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.